FindTrial
Sign In

Daratumumab IV

DRUG2 trials

Sponsors

Janssen Research & Development, LLC

Conditions

Multiple Myeloma

Phase 3

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
CompletedNCT02195479
Janssen Research & Development, LLCMultiple Myeloma
Start: 2014-12-09End: 2024-08-07Updated: 2025-08-22
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
CompletedNCT02252172
Janssen Research & Development, LLCMultiple Myeloma
Start: 2015-02-16End: 2024-10-02Updated: 2025-10-20

Related Papers

Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).
Journal of Clinical Oncology2026-05-28
Infections in Patients Receiving Daratumumab for Newly Diagnosed Multiple Myeloma: A Pooled Analysis of MAIA and ALCYONE
Blood Advances2026-05-05
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.
2025-04-094 citations
Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: <scp>MAIA</scp> Final Analysis of Patient‐Reported Outcomes
European Journal Of Haematology2025-02-143 citations
Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: analysis of key subgroups of the MAIA study.
2025-01-155 citations
Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma
Blood2024-11-052 citations
Antithrombotic utilization, adverse events, and associations with treatment outcomes in multiple myeloma: pooled analysis of three clinical trials.
2024-09-02
Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab
Blood2023-11-02
P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
HemaSphere2023-05-012 citations
Plain Language Summary of the MAIA Study of Daratumumab Plus Lenalidomide and Dexamethasone for the Treatment of People with Newly Diagnosed Multiple Myeloma
Future Oncology2023-04-012 citations
Multiples Myelom: Korrelation zwischen minimaler Resterkrankung und progressionsfreiem Überleben
Kompass Onkologie2023-01-01
Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study
Blood2022-11-1519 citations
Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial
Blood2022-11-1510 citations
Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Blood2022-11-157 citations
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials
Blood2022-09-2149 citations
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myeloma
Journal of Oncology Pharmacy Practice2022-09-0616 citations
Time to response, duration of response, and patient-reported outcomes (PROs) with daratumumab (DARA) plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM): Subgroup analysis of the phase 3 MAIA study.
Journal of Clinical Oncology2022-06-012 citations
Multiples Myelom: Daratumumab als Standard in der Erstlinientherapie bei nicht-transplantablen, neudiagnostizierten Myelompatienten
Kompass Onkologie2022-01-01
Multiples Myelom: Antikörper-basierte Regime in der Erstlinientherapie
Kompass Onkologie2022-01-01
Daratumumab in Combination for Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Oncology Times2021-12-05

21 more papers not shown